In contrast, a phase 1/2 trial recently investigated a new treatment approach in metastatic melanoma patients consisting of a subcutaneously injected vaccine against IDO and PD-L1 in combination with nivolumab. This evidence concerns the gene CD274 and metastatic melanoma.